Lilly expands manufacturing footprint in Ireland with $1.8 billion investment

Company ups manufacturing investment in Limerick by $1 billion; unveils new $800 million Kinsale facility

New investment will enhance global medicine production, benefiting millions of patients worldwide

INDIANAPOLIS, Sept. 12, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a $1 billion expansion of its Limerick, Ireland, manufacturing site to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease. The company also unveiled its new $800 million facility expansion in Kinsale, Ireland, which began making medicines last year to meet demand for Lilly's latest diabetes and obesity treatments.

This additional investment is part of the most ambitious manufacturing expansion agenda in the company's history. Since 2020, Lilly has committed more than $20 billion to build, expand and acquire manufacturing facilities in the U.S. and Europe.

"These investments will boost the production of some of our medicines, helping millions of people with diabetes, obesity and Alzheimer's disease live the healthiest lives possible," said Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations. "We won't stop there – these state-of-the-art facilities will also be equipped to support our promising pipeline molecules of the future."

Limerick, Ireland

Once complete, Limerick will join Lilly's global manufacturing network producing the biologic active ingredients for the company's Alzheimer's disease portfolio and other biologic medicines.

"Alzheimer's disease is a devastating diagnosis for both the patient and for their loved ones, along with having a huge burden on society," said Anne E. White, executive vice president and president of Lilly Neuroscience. "The treatments we will make here in Limerick offer the potential to be able to slow the progression of the disease and make life better for millions of people around the world."

Today's announcement brings Lilly's total Limerick investment to $2 billion, doubling the investment the company announced in March 2023. Advanced technologies such as machine learning, AI and automated robotics and systems at the site will enable right-first-time execution, all in support of the safe and reliable supply of medicines. As a part of this expansion, Lilly will create another 150 jobs for highly skilled workers in Limerick such as engineers, scientists, quality assurance professionals and operations personnel, for a total of 450 employees. Lilly initially announced the Limerick site in 2022 and broke ground in March 2023. Production of biologic active ingredients for Lilly medicines is on track to start in 2026.

The Limerick investment project is subject to planning approval, and the company will submit a planning application to the Limerick City and County Council in due course.

Kinsale, Ireland

Lilly remains dedicated to addressing major global health issues, and the Kinsale facility is pivotal to maintaining the safe and reliable supply of Lilly's diabetes and obesity medications. The official opening of Lilly's Kinsale manufacturing site expansion marks the completion of the state-of-the-art project to help meet the demand for current and future treatments. The site employs a digital-first process that integrates continuous manufacturing technology to create a new manufacturing platform for creating complex peptides. This facility was recently recognized as the winner of the Innovation category in the prestigious "Facility of the Year" awards program run by the International Society of Pharmaceutical Engineers.

Ireland's skilled workforce, regulatory environment and pro-innovation government policies have contributed to Lilly's nearly fifty-year presence in the country. In parallel with our manufacturing growth, Lilly's Global Business Solutions center in Cork has quadrupled employment levels since 2019, with more than 2,000 employees expected by the end of 2024, over half of whom are working in clinical research and development.

Sustainability

Lilly has a long-standing commitment to sustainability and respecting the local environment, establishing environmental programs across all sites in Ireland to monitor the quality of the ambient air, the flora and fauna and the local marine habitat. Once completed, the Limerick site will operate with 35% lower energy intensity, use 40% less water, and generate 15% less waste than traditional biopharmaceutical manufacturing processes. In Kinsale, Lilly has the single largest privately owned solar farm – 26 acres – in the Republic of Ireland, which powers a significant portion of the facility.

About Lilly 

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram and LinkedIn. C-LLY

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about planned capital investments in manufacturing sites and reflects Lilly's current beliefs and expectations. There are substantial risks and uncertainties in the manufacturing process, development, and commercialization of pharmaceutical products which could impact the overall commercial success of our products. For further discussion of risks and uncertainties relevant to Lilly's business that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-expands-manufacturing-footprint-in-ireland-with-1-8-billion-investment-302245823.html

SOURCE Eli Lilly and Company